ADVANCED DRUG RESPONSE PROFILING AND IMMUNOPHENOTYPING TO PRIORITIZE TREATMENT OPTIONS FOR PEDIATRIC MDS WITH EXCESS BLASTS
Ben Haladik(Austrian Academy of Sciences), Kaan Boztuǧ(Forschungszentrum Jülich), Luca Vinci(University Medical Center Freiburg), Marek Ussowicz(Wroclaw Medical University), Fabio D. Steffen(University Children's Hospital Zurich), Jean‐Pierre Bourquin(University Children's Hospital Zurich), Margarita Maurer‐Granofszky(St Anna Children's Hospital), Michael Dworzak(St. Anna Children's Cancer Research Institute), Nastassja K. Scheidegger(University of Zurich), Barbara De Moerloose(Ghent University Hospital), Silvia Gutnik(University Children's Hospital Zurich), Henrik Hasle(Aarhus University Hospital), Charlotte M. Niemeyer(University of Freiburg), Miriam Erlacher(University Hospital Ulm), Ayami Yoshimi Noellke(University Medical Center Freiburg), Anna Hurt(St Anna Children's Hospital), Markus Schmugge(University Children's Hospital Zurich), Claudia M. Koelbl(St Anna Children's Hospital), Beat Bornhäuser(University Children's Hospital Zurich)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577